JPRN-UMIN000008626已完成2 期
Phase II trial of Trastuzumab + CPT-11 therapy for HER2-positive advanced gastric cancer patients with prior chemotherapy - CPT-11 + Trastuzumab therapy for patients with prior chemotherapy (HERBIS-5)
Osaka Gastrointestinal cancer chemotherapy Study Group (OGSG)0 个研究点目标入组 30 人开始时间: 2012年8月6日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. with active double cancer 2. with prior chemotherapy of CPT-11 3. with local/general active infectious disease 4. Serious complication as followings, a.bleeding on digestive tract b.Ileus c.intestinal paralysis d. Interstitial pneumonia e. Pulmonary fibrosis f. ischemic heart disease or cardiac dysrhythmia requiring treatment g. Heart failure h. Renal failure i. Hepatic cirrhosis j. glaucoma k. Uncontrolled diabetes mellitus 5. with uncontrollable diarrhea 6. with a history of severe allergy 7. with a middle or large volume of ascites and/or pleural fluid 8. with a continuous administration of steroids 9. with a difficulty on registration to This study due to psychological disease 10. with a central nerve metastasis 11. With administration of atazanabil 12. Women in pregnancy, at risk of pregnancy, hoping to become pregnant. Men who want their partners to become pregnant. 13. Patients have Active hepatitis type B and/or hepatitis C. 14. Any patients judged by the investigator to be unfit to participate in the study
研究者
相似试验
已完成
2 期
Phase II trial of Trastuzumab in combination with Abraxane for patients with HER2-positive metastatic breast cancerHER2-positive Metastatic breast cancerJPRN-UMIN000006159Kumamoto Breast Cancer Cooperative Group23
进行中（未招募）
1 期
Study of trastuzumab in combination with pertuzumab in patients already treated with a lung cancer harboring a Her2 mutation and receiving docetaxelon small cell lung cancer with a Her2 mutationMedDRA version: 21.1Level: PTClassification code 10029519Term: Non-small cell lung cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 23.0Level: PTClassification code 10075653Term: HER2 gene amplificationSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2018-003506-11-FRIFCT45
已完成
2 期
Phase II trial of TS-1 plus Trastuzumab in patients with metastatic breast cancerbreast cancerJPRN-UMIN000004764Tokai University School of Medicine30
已完成
2 期
Phase II trial of trasutuzumab plus docetaxel for previous trastuzumab treated unresectable or recurrent HER2 positive gastric cancer (T-CORE1203)HER2 positive gastric cancerJPRN-UMIN000010869Tohoku Clinical Oncology, Research and Education Society(T-CORE)27
已完成
2 期
Randomized phase II trial evaluating trastuzumab + capecitabine (HX) or lapatinib + capecitabine (LX) in HER2-positive metastatic breast cancer patients previously treated with trastuzumab and taxanesHER2-positive metastatic breast cancerJPRN-UMIN000005219West Japan Oncology Group110